MOMA 313
Alternative Names: MOMA-313Latest Information Update: 08 Oct 2024
Price :
$50 *
At a glance
- Originator MOMA Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA polymerase theta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 13 Aug 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in USA (PO) (NCT06545942)
- 13 Aug 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in USA (PO) (NCT06545942)
- 12 Aug 2024 MOMA Therapeutics plans phase-I trial for Solid tumours (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease) in August 2024 (PO) (NCT06545942)